Gilteritinib also downregulated Mcl-1, a commonly overexpressed culprit to venetoclax resistance.124 Additionally, this combination is being tested in a phase I clinical trial that is currently recruiting subjects with R/R AML (NCT03625505). Here, MCL1 is linked to acute myeloid leukemia.